Background: The heparan sulfate proteoglycan, syndecan-1 (also known as CD138), is associated with cell proliferation, adhesion, and migration in various types of human malignancies. The role of syndecan-1 in soft tissue tumors is unknown; therefore we examined whether syndecan-1 plays a role in human liposarcoma.
Introduction
Liposarcoma is the most common soft tissue sarcoma, accounting for at least 20% of all sarcomas in adults (Mack, 1995) . Histologically, liposarcomas can be divided into three categories: atypical lipomatous tumor/well-differentiated liposarcoma/dedifferentiated liposarcomas, myxoid liposarcomas, and pleomorphic liposarcomas. The most important prognostic factor of atypical lipomatous tumor and dedifferentiated liposarcoma is anatomic location (Fletcher, Bridge, Hogendoorn, & Mertens, 2013) . For localized myxoid liposarcoma, high histological grade (often defined as >5% round cell component), presence of necrosis, and alterations in TP53 and CDKN2A are predictors of unfavorable outcome (Fletcher et al., 2013) . For pleomorphic liposarcoma, central location, tumor depth, size and mitotic index have been associated with a worse prognosis (Fletcher et al., 2013) . The recurrence rate for atypical lipomatous tumors, dedifferentiated liposarcomas, myxoid liposarcomas and pleomorphic liposarcomas are 63, 14, 41, and 43%, respectively; associated mortalities for these tumors are 11, 31, 28 and 35%, respectively (Weiss & Rao, 1992; Kilpatrick, Doyon, Choong, Sim, & Nascimento, 1996; Henricks, Chu, Goldblum, & Weiss, 1997; Gebhard et al., 2002) .
Surgery serves as the sole therapy for localized liposarcomas. Generally, liposarcomas are known to be a relatively chemoresistant tumor, with the exception of the myxoid variant. Conventional chemotherapy with doxorubicin and ifosfamide is the first-line treatment for liposarcomas. Other active cytotoxic agents include gemcitabine, docetaxel and the marine-derived compound trabectedin (Kollár & Benson, 2014) . Moreover, liposarcomas, excluding the myxoid variant, are highly resistant to radiotherapy. Liposarcoma patients with metastases or poor response to chemotherapy have worse prognosis; therefore a new therapeutic drug is required. and angiogenesis (Bernifield et al., 1999) . In hematologic disorders, syndecan-1 expression marks hematopoietic cells with plasmacytic differentiation, as well as other B-cell-lineage hematopoietic neoplasms such as immunoblastic diffuse large B-cell lymphoma and marginal zone lymphoma (O'Connell, J. L. Pinkus, & G. S. Pinkus, 2004) . Syndecan-1 expression is dysregulated in many cancers, and its expression is associated with prognosis in squamous cell carcinomas of the head and neck (Inki, Joensuu, Grénman, Klemi, & Jalkanen, 1994; Anttonen, Kajanti, Heikkila, Jalkanen, & Joensuu, 1999) , colorectal, pancreatic and prostate adenocarcinoma (Day et al., 1999; Conejo et al., 2000; Zellweger et al., 2003) , breast carcinoma (Loussouarn et al., 2008) , renal cell carcinoma (Gökden et al., 2006) , hepatocellular carcinoma (Matsumoto et al., 1997) , and malignant mesothelioma (Kumar-Singh et al., 1998) . We previously reported increased levels of syndecan-1 expression in prostate adenocarcinoma and urothelial carcinoma, suggesting that increased syndecan-1 expression contributes to cancer progression (Shimada et al., 2009; Shimada et al., 2010) . Syndecan-1 is not readily detected by immunohistochemistry in differentiated benign mesenchymal cells or tumors. Low expression levels of syndecan-1 are produced by cultured endothelial cells (Elenius & Jalkanen, 1994) . Although expression has been reported in some other soft tissue tumor cells (O'Connell et al., 2004; Orosz & Kopper, 2001) , the role of syndecan-1 in liposarcomas remains unknown.
We conducted a clinicopathologic and prognostic analysis of syndecan-1 expression in 42 liposarcoma specimens and their benign counterparts. We examined the roles of syndecan-1 in liposarcoma by in vitro studies. Syndecan-1 overexpression was correlated to a poor prognostic factor for recurrence-free survival in myxoid liposarcoma patients. In addition, syndecan-1 silencing through siRNA transfection effectively induced cellular apoptosis and growth suppression of liposarcoma cells in vitro. We found that cell growth and clinical recurrence might be enhanced by syndecan-1 in human myxoid liposarcoma.
Materials and Methods

Cell Culture
The human liposarcoma cell line SW872 was purchased from the American Type Culture Collection (Rockville, MD, USA). Cells were maintained in Leibovitz's L-15 medium with 12% fetal bovine serum at 37 °C/5% CO 2 .
RNA Silencing of Syndecan-1
We seeded 8 × 10 4 SW872 cells per well in six-well culture dishes. Cells were transfected with 132 nM short interfering RNAs (siRNAs) specific for syndecan-1 (Qiagen, Venlo, Netherlands). Transfections were carried out using Lipofectamine RNAiMAX (Life Technologies, Foster City, CA, USA) in accordance with the manufacturer's protocol. The syndecan-1 siRNA sequence (5′-TCC GAC TGC TTT GGA CCT AAA-3′) was designed following selection of appropriate DNA target sequences.
Extraction of Total RNA and Reverse-Transcription Polymerase Chain Reaction (RT-PCR) Assays
We extracted total RNA from samples using an RNeasy Mini kit (Qiagen). We synthesized cDNA from 1 μg of purified total RNA using PrimeScript RT Master Mix (Perfect Real Time; Takara, Shiga, Japan) and SYBR Premix Ex Taq II (TliRNaseH Plus; Takara). Each reaction was subjected to thermal cycling at 95 °C for 30 s and 55-63 °C for 30 s over 35-45 cycles. The amount of actin mRNA was used to standardize the quantity of syndecan-1 mRNA. Primers are as follows: actin sense, 5′-ATGGGTCAGAAGGATTCCTATGT-3′ and actin antisense, 5′-GAAGGTCTCAAACATGATCTGGG-3′; and syndecan-1 sense, 5′-GGCTGTAGTCCTGCCAGAAG-3′ and antisense, 5′-GTTGAGGCCTGATGAGTGGT-3′.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick end Labeling (TUNEL) Assays
DNA cleavage, a characteristic of apoptosis, was detected using the TUNEL assay (Apop Tag Plus Peroxidase In situ Apoptosis Detection Kit; Millipore, Temecula, CA, USA). After siRNA transfection, cells were washed with phosphate-buffered saline once for 3 min and fixed with CytoRich Red (Becton-Dickinson, Franklin Lakes, NJ, USA) at room temperature for 30 min. The fixed cells were washed with distilled water once for 3 min, deposited on a slide, further fixed in 95% ethanol, and stained with the above kit. At least 600 cells from three different fields of view were examined from each experiment. Cell death was expressed as the percentage of TUNEL-positive cells.
Cell Proliferation Assays
Cells were stimulated with various reagents and then treated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphonyl)-2H-tetrazolium (Promega, Tokyo, Japan), a tetrazolium salt. After asiRNA. All experiments were performed in triplicate.
Tissue Samples
After obtaining approval from our institutional review board, we searched the surgical pathology database of our institution for the period July 1984 to June 2012. As shown in Table 1 , we examined 42 cases of liposarcoma (14 atypical lipomatous tumors, six dedifferentiated liposarcomas, 21 myxoid liposarcomas, and one pleomorphic liposarcoma), 34 cases of lipoma and 20 cases of normal adipose tissue. The liposarcoma specimens included 27 primary tumors and 15 local recurrent or distant metastatic tumors. Only myxoid liposarcoma specimens included 10 primary, 10 local recurrent and 1 distant metastatic tumors. Diagnoses for all of these tumors were made according to the latest edition of the World Health Organization classification scheme (Fletcher et al., 2013) . In regard to myxoid liposarcoma, fluorescence in situ hybridization analysis of the DNA damage-inducible transcript 3 (DDIT3) and fused in sarcoma (FUS) loci was performed in three of the 21 examined cases. We found that 3/3 cases showed both DDIT3 and FUS gene rearrangements. Clinical details and follow-up information were obtained by reviewing medical charts. The clinicopathologic characteristics of myxoid liposarcoma are summarized in Table 2 . The 21 cases included 11 men and 10 women with an age range of 28-83 years (median, 52 years). Tumors were located in the extremities for 15 cases (thigh, 11; lower leg, three; forearm, one), in the trunk wall in five cases (buttock, three; abdominal wall, two), and in the retroperitoneum in one case. All primary tumors were treated with surgery, accompanied by adjuvant chemotherapy or irradiation in eight cases. For staging of the tumors, the latest American Joint Committee on Cancer (AJCC) staging system was used (Edge et al., 2010) . The median follow-up period after surgery was 79 months (range, 5-244 months). Recurrence-free survival was defined as the interval from diagnosis to discovery of a local recurrence or the last follow-up examination.
Immunohistochemistry
Immunohistochemical staining for syndecan-1, Ki-67, MDM2 and p16 was performed. A previous study showed that cell surface syndecan-1 binds to hepatocyte growth factor (HGF) via heparan sulfate chains and promotes Met activation, leading to myeloma cell growth and survival (Teng, Aquino, & Park, 2012) . Thus, membranous expression of syndecan-1 was considered a positive signal. The levels of syndecan-1 and Ki67 immunostaining were graded according to the proportion of positively stained cells (negative, <10%; positive, ≥10%). The levels of MDM2 and p16 immunostaining were graded according to the proportion of positively stained cells (negative, <1%; positive, ≥1%). Tumor tissue from each case was fixed in 10% neutral-buffered formalin and embedded in paraffin. Specimens were cut at 4 µm intervals and mounted for immunohistochemical analysis and histopathological analysis by conventional hematoxylin and eosin (HE) staining. The HE-stained sections served as a guide for immunohistochemical analyses. After deparaffinization in xylene and sequential hydration in 100 and 95% ethanol, sections were heated 120 °C for 10 min in 10 mM sodium citrate buffer (pH 6.0) and incubated with antibodies against syndecan-1 (1:20 dilution; clone MI15; Thermo Fisher Scientific, Rockford, IL, USA), Ki-67 (1:1; clone SP6; Nichirei, Tokyo, Japan), MDM2 (1:250; clone IF2; Life Technologies) and p16 (1:50; clone JC8; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Immunoreactivity was visualized using a Histofine SAB-PO kit with diaminobenzidine as the chromogen (Nichirei), and hematoxylin counterstaining.
Statistical Analysis
A t-test was used for comparison of means between two independent samples. Levene test was applied to verify the homoscedasticity. The univariate relationship between each clinicopathological variable and syndecan-1 expression was evaluated using the chi-squared test or Fisher's exact test. Recurrence-free survival was analyzed for 21 myxoid liposarcoma patients. Recurrence-free survival was estimated by the Kaplan-Meier method. The log-rank test was used to evaluate the differences between survival curves. These analyses were performed with IBM SPSS ver. 20.0 (IBM Co., Armonk, NY, USA). A p-value less than 0.05 was considered statistically significant for all tests.
Results
Syndecan-1 Immunostaining and Prognostic Significance
As a pilot study, we previously examined syndecan-1 expression by immunohistochemistry in 158 soft tissue sarcomas and found significant results in lipomatous tumors. Syndecan-1 expression was observed in 12% of all liposarcomas but not in lipomas and normal adipose tissue ( No significant association between syndecan-1 expression and prognosis in each subtype of liposarcoma was detected (data not shown), except in myxoid liposarcomas. Therefore, we summarized the correlation between syndecan-1 immunopositivity and myxoid liposarcoma clinicopathologic factors in Table 2 . Immunohistochemistry of myxoid liposarcoma showed that syndecan-1 was expressed in both the nucleus and the cell membrane (Figure 1 ).
www.ccsenet.org/cco Cancer and Clinical Oncology Vol. 4, No. 1; A B Figure 1 . Myxoid liposarcoma. Immunohistochemical analysis showed that syndecan-1 is expressed in both the nucleus and the cell membrane (A, ×100; B, ×400).
The two cases of syndecan-1 positive myxoid liposarcoma were primary and local recurrent tumors. Positive syndecan-1 staining showed a significant association with unfavorable recurrence-free survival of myxoid liposarcoma patients by a univariate prognostic analysis (p = 0.023; Table 3 ; Figure 2 ). Male was also associated with poor prognosis (p = 0.04; Table 3 ). We also investigated the relationships between percentage of syndecan-1 positive tumor cells and overall or metastatic-free survival in myxoid liposarcoma patients using the Kaplan-Meier method. We found no significant associations between percentage of syndecan-1 positive tumor cells and outcomes (data not shown). Vol. 4, No. 1; Figure 2. Kaplan-Meier analysis of recurrence-free survival in myxoid liposarcoma patients with syndecan-1 expression
Syndecan-1 Silencing Induced Apoptosis
Expression of syndecan-1 mRNAs was reduced by transfection with specific siRNAs ( Figure 3A) . Silencing of the syndecan-1 gene was confirmed by western blotting (data not shown). Cell growth was significantly suppressed 72 h after transfection with syndecan-1 siRNAs ( Figure 3B ). The proportion of apoptotic cells, as assessed by TUNEL assays, increased in response to syndecan-1 knockdown (control RNA vs. syndecan-1 siRNA, 0.58 ± 0.015 vs. 2.72 ± 0.398%; p = 0.033; Figure 3C ). Vol. 4, No. 1; subjected to TUNEL assays. Each value is presented as the mean ± SE. *P < 0.05.
Discussion
In our study, prognostic analyses showed that syndecan-1 expression might be an unfavorable prognostic factor for recurrence-free survival in myxoid liposarcoma patients (P < 0.05). However, owing to the patient numbers, statistical power is weak and thus is a limitation of this study. Previous studies on the roles of syndecan-1 during neoplastic transformation and progression of various human malignancies revealed various findings dependent on tumor type (Sanderson & Borset, 2002) . In squamous cell carcinomas of the head and neck (Inki et al., 1994; Anttonen et al., 1999) , colorectal adenocarcinoma (Day et al., 1999) , breast carcinoma (Loussouarn et al., 2008) , renal cell carcinoma (Gökden et al., 2006) , hepatocellular carcinoma (Matsumoto et al., 1997) and malignant mesothelioma (Kumar-Singh et al., 1998) , downregulation of syndecan-1 expression was observed with tumor progression. In contrast, increased syndecan-1 expression was seen in pancreatic and prostate adenocarcinomas compared with their benign counterparts (Conejo et al., 2000; Zellweger et al., 2003) . Thus, syndecan-1 might have varying effects on the progression of different tumor types. Limited data are available regarding the prognostic value of syndecan-1 expression in soft tissue sarcomas (O'Connell et al., 2004; Orosz et al., 2001 ).
Our results suggest that syndecan-1 immunohistochemistry may help us to predict the risk of local recurrence of myxoid liposarcomas prior to clinical treatment.
In the present study, syndecan-1 knockdown suppressed cell growth through the induction of apoptosis in human liposarcoma cells. Syndecan-1 gene silencing induced growth arrest and apoptosis in myeloma cells. This could be because of diminished pro-survival signals as a result of reduced levels of cell surface heparan sulfate proteoglycan co-receptors for growth factor signaling (Khotskaya et al., 2009 ). This mechanism also applies to liposarcoma cells. Moreover, syndecan-1 synergizes with heparanase to promote myeloma bone disease by activating the HGF-Met-IL-11-RANKL signaling pathway (Teng et al., 2012) . Therapy targeting the syndecan-1/heparanase axis can block the aggressive behavior of tumors, and could lead to new tumor therapies against drug-resistant cancers or sarcomas. Thus, our findings suggest that a therapy directly targeting syndecan-1 and heparanase inhibitors should be effective against myxoid liposarcomas.
In summary, our results show that syndecan-1 overexpression may be associated with unfavorable recurrence-free survival in myxoid liposarcoma patients. In addition, syndecan-1 may be essential for cell growth in liposarcoma in vitro. Therefore, syndecan-1 could represent a new molecular target and a useful clinicopathological marker in myxoid liposarcoma.
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